Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 12
1998 26
1999 62
2000 96
2001 146
2002 125
2003 155
2004 166
2005 220
2006 214
2007 233
2008 259
2009 252
2010 312
2011 316
2012 321
2013 359
2014 334
2015 360
2016 339
2017 353
2018 329
2019 386
2020 453
2021 411
2022 435
2023 179

Text availability

Article attribute

Article type

Publication date

Search Results

6,124 results

Results by year

Filters applied: . Clear all
Page 1
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Dorman SE, et al. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. N Engl J Med. 2021. PMID: 33951360 Free PMC article. Clinical Trial.
In one 4-month regimen, rifampin was replaced with rifapentine; in the other, rifampin was replaced with rifapentine and ethambutol with moxifloxacin. The primary efficacy outcome was survival free of tuberculosis at 12 months. ...Adverse events of grade 3 or higher occurr …
In one 4-month regimen, rifampin was replaced with rifapentine; in the other, rifampin was replaced with rifapentine and ethambutol with …
Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Stets R, et al. N Engl J Med. 2019 Feb 7;380(6):517-527. doi: 10.1056/NEJMoa1800201. N Engl J Med. 2019. PMID: 30726692 Clinical Trial.
RESULTS: The intention-to-treat population included 386 patients in the omadacycline group and 388 patients in the moxifloxacin group. Omadacycline was noninferior to moxifloxacin for early clinical response (81.1% and 82.7%, respectively; difference, -1.6 percentag …
RESULTS: The intention-to-treat population included 386 patients in the omadacycline group and 388 patients in the moxifloxacin group …
Protection of the Human Gut Microbiome From Antibiotics.
de Gunzburg J, Ghozlane A, Ducher A, Le Chatelier E, Duval X, Ruppé E, Armand-Lefevre L, Sablier-Gallis F, Burdet C, Alavoine L, Chachaty E, Augustin V, Varastet M, Levenez F, Kennedy S, Pons N, Mentré F, Andremont A. de Gunzburg J, et al. J Infect Dis. 2018 Jan 30;217(4):628-636. doi: 10.1093/infdis/jix604. J Infect Dis. 2018. PMID: 29186529 Free PMC article. Clinical Trial.
METHODS: We performed a randomized controlled trial in 28 human volunteers treated with a 5-day clinical regimen of the fluoroquinolone antibiotic moxifloxacin in 2 parallel groups, with or without DAV132 coadministration. Two control goups of 8 volunteers each receiving D …
METHODS: We performed a randomized controlled trial in 28 human volunteers treated with a 5-day clinical regimen of the fluoroquinolone anti …
2021 European guideline on the management of Mycoplasma genitalium infections.
Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. Jensen JS, et al. J Eur Acad Dermatol Venereol. 2022 May;36(5):641-650. doi: 10.1111/jdv.17972. Epub 2022 Feb 19. J Eur Acad Dermatol Venereol. 2022. PMID: 35182080
Second-line treatment and treatment for uncomplicated macrolide-resistant M. genitalium infection: Moxifloxacin 400 mg od for 7 days (oral). Third-line treatment for persistent M. genitalium infection after azithromycin and moxifloxacin: Doxycycline or minocycline 1 …
Second-line treatment and treatment for uncomplicated macrolide-resistant M. genitalium infection: Moxifloxacin 400 mg od for 7 days …
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
In stage 2 of the trial, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) was compared with a 9-to-20-month standard-care regimen. ...
In stage 2 of the trial, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) was compared with a 9-to-2 …
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
Tang HJ, Wang JH, Lai CC. Tang HJ, et al. Medicine (Baltimore). 2020 Jul 17;99(29):e21223. doi: 10.1097/MD.0000000000021223. Medicine (Baltimore). 2020. PMID: 32702892 Free PMC article. Clinical Trial.
The early clinical response rate was 89.3% and 90.5% among lefamulin and moxifloxacin group, respectively. Lefamulin was noninferior to moxifloxacin (89.3% vs 90.5%, RR: 0.99, 95% CI: 0.95-1.02, I = 0%). ...Lefamulin was associated with a similar risk of adverse eve …
The early clinical response rate was 89.3% and 90.5% among lefamulin and moxifloxacin group, respectively. Lefamulin was noninferior …
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID; STREAM Study Collaborators. Nunn AJ, et al. N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13. N Engl J Med. 2019. PMID: 30865791 Free article. Clinical Trial.
Participants were randomly assigned, in a 2:1 ratio, to receive a short regimen (9 to 11 months) that included high-dose moxifloxacin or a long regimen (20 months) that followed the 2011 WHO guidelines. ...
Participants were randomly assigned, in a 2:1 ratio, to receive a short regimen (9 to 11 months) that included high-dose moxifloxacin …
Endophthalmitis after cataract surgery: an update on recent advances.
Peck TJ, Patel SN, Ho AC. Peck TJ, et al. Curr Opin Ophthalmol. 2021 Jan;32(1):62-68. doi: 10.1097/ICU.0000000000000727. Curr Opin Ophthalmol. 2021. PMID: 33196543 Review.
RECENT FINDINGS: The IRIS registry indicates the rates of endophthalmitis are decreasing in the United States, and the outcomes appear to be improving. Intracameral moxifloxacin has become more widely accepted and intracameral vancomycin has been shown to be associated wit …
RECENT FINDINGS: The IRIS registry indicates the rates of endophthalmitis are decreasing in the United States, and the outcomes appear to be …
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.
Torres A, Garrity-Ryan L, Kirsch C, Steenbergen JN, Eckburg PB, Das AF, Curran M, Manley A, Tzanis E, McGovern PC. Torres A, et al. Int J Infect Dis. 2021 Mar;104:501-509. doi: 10.1016/j.ijid.2021.01.032. Epub 2021 Jan 20. Int J Infect Dis. 2021. PMID: 33484864 Free article. Clinical Trial.
Clinical success rates with omadacycline and moxifloxacin were similar against identified pathogens and across key subgroups. CONCLUSIONS: Omadacycline was non-inferior to moxifloxacin for IACR at PTE, with high clinical success across pathogen types and patient sub …
Clinical success rates with omadacycline and moxifloxacin were similar against identified pathogens and across key subgroups. CONCLUS …
Reply.
Melega MV, Alves M, Cavalcanti Lira RP, Cardoso da Silva I, Ferreira BG, Assis Filho HLG, Pedreira Chaves FR, Martini AAF, Dias Freire LM, Reis RD, Leite Arieta CE. Melega MV, et al. J Cataract Refract Surg. 2019 Jun;45(6):890-891. doi: 10.1016/j.jcrs.2019.03.027. J Cataract Refract Surg. 2019. PMID: 31146948 No abstract available.
6,124 results